Tradename: ODACTRA Proper Name: House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract Indication: To include use in adolescents 12 through 17 years of age. ODACTRA is an allergen…
Tradename: ADACEL Proper Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed Indication: To include immunization during the third trimester of pregnancy to prevent pertussis in infants younger…
Drug Name: Leqembi Indications: To treat Alzheimer’s disease Active Ingredient: Lecanemab-irmb Company: Eisai Inc Approval Date: 1/6/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf
Drug Name: Brenzavvy Indications: To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Active Ingredient: Bexagliflozin Company: TheracosBio, LLC Approval…
Drug Approval Name: Briumvi Active Ingredient: ublituximab-xiiy Indications: To treat relapsing forms of multiple sclerosis Approval Date: 12/28/2022 Company: TG Therapeutics, Inc. Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf
Name: NexoBrid Active Ingredient: anacaulase-bcdb Indications: To remove eschar in adults with deep partial thickness or full thickness thermal burns Approval Date: 12/28/2022 Company: MediWound LTD Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf
Name: Xenoview Active Ingredient: hyperpolarized Xe-129 Indications: To evaluate pulmonary function and imaging Approval Date: 12/23/2022 Company: Polarean, Inc. Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf
Drug Name: Sunlenca Active Ingredient: lenacapavir Indications: To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations…
Drug Name: Lunsumio Active Ingredient: mosunetuzumab-axgb Indications: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma Approval Date: 12/22/2022 Company: Genentech, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
Drug Name: Krazati Active Ingredient: adagrasib Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy…